70 In the STEP HFpEF trial, higher changes in KCCQ-CSS were linearly associated with weight loss with semaglutide (5.9-point increase in KCCQ-CSS per 10% body weight loss)
Sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin are the current DPP4is on the market, which are usually prescribed for T2DM subjects who have poor glycemic control with lifestyle and metformin ( Tables 1 and 2 )
The drugs achieve these benefits by mimicking GLP-1s effects: They stimulate insulin production by binding to beta-cells in the pancreas
Impaired glucose tolerance as a disorder of insulin action
The Retatrutide starting dose is 2 mg administered subcutaneously once per week
Patients often feel satisfied sooner during meals, are less interested in second portions, and begin to experience calmer, more predictable hunger patterns throughout the day